Novocure nabs reimbursement for Optune in Japan

Novocure (NSDQ:NVCR) shares were up this morning after the Japanese Ministry of Health, Labour and Welfare agreed to reimburse for Optune as a treatment for newly-diagnosed glioblastoma.

The Optune device delivers low-intensity, intermediate frequency, alternating electric fields, called “Tumor Treating Fields,” to inhibit cancer cell replication. As a treatment for newly-diagnosed glioblastoma, Novocure combines its device with the anti-cancer drug temozolomide.

Get the full story at our sister site, Drug Delivery Business News.

The post Novocure nabs reimbursement for Optune in Japan appeared first on MassDevice.

from MassDevice http://ift.tt/2AkIhgK